Moderna, Inc. News
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
see moreModerna, Inc. Market News
22d
Moderna Rally: FDA Sets PDUFA for mRNA-1010 Boost!
- Moderna shares jumped after the FDA agreed to review the company's seasonal flu candidate mRNA-1010 and set an August 5, 2026 PDUFA date. Combined with durable oncology data from the personalized cancer vaccine V940, the regulatory milestone has become a clear near-term catalyst for NASDAQ: MRNA.
29d
Moderna Slides After FDA RTF Reversal; Aug 5 PDUFA
Moderna (MRNA) saw modest share weakness and thin volume last week amid no new clinical data or legal developments. The stock remains anchored by a recent LNP patent settlement and the August 5, 2026 PDUFA date for its seasonal flu candidate. Investors are in wait-and-see mode ahead of regulatory and oncology milestones.
03 Apr at 10:48
Moderna Surge: $950M Patent Deal Sparks Rally Now!
Moderna (MRNA) jumped after settling LNP patent litigation with a $950M one-time payment and the FDA agreeing to review its seasonal flu mRNA-1010 application. Combined with a solid Q4 beat and optimistic guidance, these concrete developments removed major overhangs and drove a multiweek stock rally.
27 Mar at 10:48
Moderna Rally: Patent Deal Sparks Stock Surge Up!!
Moderna stock jumped after a settlement over lipid nanoparticle patents and a regulatory milestone for its flu vaccine. The agreement reduces legal overhang, secures licensing terms without ongoing royalties, and sets a clear PDUFA date for mRNA-1010—catalysts that drove the recent double-digit gains in MRNA shares.
13 Mar at 10:48
Moderna LNP Settlement, FDA Sets Flu PDUFA Date Q3
Moderna disclosed a major settlement resolving lipid‑nanoparticle patent litigation and secured FDA acceptance for its seasonal flu mRNA vaccine application with a PDUFA date in August 2026. Both developments triggered sharp stock moves and reduce key execution risks as the company pivots beyond COVID‑19 revenues.
06 Mar at 10:48
Moderna Rally: FDA Reversal, Q4 Strength & Risks!!
Moderna (MRNA) saw a near-term rebound after the FDA agreed to review its mRNA flu shot application and the company posted stronger-than-expected Q4 results alongside aggressive cost cuts. Near-term catalysts include a March patent trial, oncology readouts later in 2026, and international regulatory reviews for combination vaccines.
27 Feb at 10:48
Moderna FDA Reversal Spurs mRNA-1010 Rally Shares!
Moderna's shares jumped after the FDA reversed a refusal-to-file for its seasonal mRNA flu vaccine, mRNA-1010. Analyst target hikes, leadership shifts toward oncology, and cost cuts support the rally. This article summarizes the concrete regulatory, financial, and strategic developments that are driving near-term investor sentiment for MRNA.